Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verdiperstat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO known ✓ | P05164 | 19/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | TPO | P07202 | 17/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29879357 | 0.82 | MPO (0.70) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL8223760 | 0.80 | MPO (0.67) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL1536784 | 0.80 | MPO (0.66) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL18557964 | 0.80 | MPO (0.66) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL1536701 | 0.79 | MPO (0.64) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL28896602 | 0.79 | MPO (0.65) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL28896567 | 0.79 | MPO (0.65) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL4257613 | 0.78 | MPO (0.64) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL21530641 | 0.77 | MPO (0.63) | MPOOPRM1TPOKCNH2CYP3A4 | |
| SCHEMBL4259212 | 0.77 | MPO (0.62) | MPOOPRM1TPOKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2025227119-A1 | MYELOPEROXIDASE FLUORESCENCE IMAGING | THE GENERAL HOSPITAL CORPORATION (US) | 2025-10-30 | — | — | WO | claimed |
| US-12383158-B2 | Detection of high-risk unstable atherosclerotic plaque | THE HEART RESEARCH INSTITUTE LTD (AU) | 2025-08-12 | — | — | US | claimed |
| WO-2024215723-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | YALE UNIVERSITY (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024095118-A1 | DOSING REGIMEN OF A CSF-1R INHIBITOR FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NOVARTIS AG (CH) | 2024-05-10 | — | — | WO | claimed |
| US-20240138701-A1 | DETECTION OF HIGH-RISK UNSTABLE ATHEROSCLEROTIC PLAQUE | THE HEART RESEARCH INSTITUTE LTD (AU) | 2024-05-02 | — | — | US | claimed |
| EP-3654983-B1 | MPO INHIBITORS FOR USE IN MEDICINE | ASTRAZENECA AB (SE) | 2023-08-30 | — | — | EP | claimed |
| US-11738027-B2 | MPO inhibitors for use in medicine | ASTRAZENECA AB (SE) | 2023-08-29 | — | — | US | claimed |
| US-20230192702-A1 | PROCESS FOR THE PREPARATION OF VERDIPERSTAT | BIOHAVEN THERAPEUTICS LTD (US) | 2023-06-22 | — | — | US | claimed |
| US-20230130225-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH MYELOPEROXIDASE INHIBITOR | BIOHAVEN THERAPEUTICS LTD (US) | 2023-04-27 | — | — | US | claimed |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2014-08-07 | — | — | US | claimed |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2013-03-07 | — | — | US | claimed |
| EP-2200616-B1 | MIPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND MULTIPLE SYSTEM ATROPHY | ASTRAZENECA AB (SE) | 2012-12-26 | — | — | EP | claimed |
| EP-1824855-B1 | Novel pyrrolo [3, 2-d]pyrimidin-4-one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | claimed |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | claimed |
| US-20090054468-A1 | New Use 938 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | claimed |
| JP-2008522968-A | — | — | 2008-07-03 | — | — | JP | claimed |
| EP-1824855-A1 | NOVEL PYRROLO [3, 2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | claimed |
| WO-2006062465-A1 | NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130225-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH MYELOPEROXIDASE INHIBITOR | SOD1, MPO, CAT | MPO 2/4885OPRM1 2052/4885TPO 187/4885 |
| US-11738027-B2 | MPO inhibitors for use in medicine | MPO, SERPINB1, MMP8 | MPO 1/4885OPRM1 396/4885TPO 23/4885 |
| US-20140221400-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885OPRM1 2040/4885TPO 87/4885 |
| US-20230192702-A1 | PROCESS FOR THE PREPARATION OF VERDIPERSTAT | GNPAT, DDT, AASDHPPT | MPO 1231/4885OPRM1 1566/4885TPO 2824/4885 |
| US-20130059870-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885OPRM1 2040/4885TPO 87/4885 |
| US-20080221136-A1 | neuroinflammatory, cardiovascular and respiratory disorders; inhibitors of Myeloperoxidase found predominantly in polymorphonuclear leukocytes; 1-butyl-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one | MPO, EPX, SERPINB1 | MPO 1/4885OPRM1 620/4885TPO 50/4885 |
| US-20090054468-A1 | New Use 938 | MPO, CAT, HTT | MPO 1/4885OPRM1 2106/4885TPO 199/4885 |
| US-20110207755-A1 | USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938 | MPO, CAT, HTT | MPO 1/4885OPRM1 2040/4885TPO 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.